Source: Υπουργείο Υγείας (CY) Revision Year: 2021 Publisher: Remedica Ltd, Aharnon Street, Limassol Industrial Estate, 3056 Limassol, Cyprus
Felexin 250 mg hard capsules.
Felexin 500 mg hard capsules.
| Pharmaceutical Form |
|---|
|
Hard capsules. Green/White capsules. |
Felexin 250 mg hard capsules:
Each hard capsule contains cefalexin monohydrate equivalent to 250 mg cefalexin.
Felexin 500 mg hard capsules:
Each hard capsule contains cefalexin monohydrate equivalent to 500 mg cefalexin.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Cefalexin |
Cefalexin is an antibacterial agent of the cephalosporin class. Like other cephalosporins cefalexin exerts antibacterial activity by binding to and inhibiting the action of penicillin-binding proteins involved in the synthesis of bacterial cell walls. This leads to bacterial cell lysis and cell death. |
| List of Excipients |
|---|
|
Capsule content: Sodium starch glycolate (Type A) Capsule shell: Titanium dioxide E171 |
Felexin 250 mg hard capsules:
PVC/Aluminium Blisters. Pack sizes of 20 and 100 hard capsules.
PP containers with PE closures. Pack sizes of 500 and 1000 hard capsules.
Felexin 500 mg hard capsules:
PVC/Aluminium Blisters. Pack sizes of 16, 20, 100 and 1000 hard capsules.
PP containers with PE closures. Pack sizes of 500 and 1000 hard capsules.
Not all pack sizes may be marketed.
Remedica Ltd, Aharnon Street, Limassol Industrial Estate, 3056 Limassol, Cyprus
Felexin 250 mg hard capsules: 19696
Felexin 500 mg hard capsules: 19701
Date of first authorization: 15 July 2005
Date of latest renewal: 17 June 2011
| Drug | Countries | |
|---|---|---|
| FELEXIN | Cyprus, Malta, Singapore |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
